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ABSTRACT
Purpose. Limited information is available about the op-
timal management and clinical outcome of bone-only
metastases in breast cancer patients. The objective of
this study was to define prognostic factors for patients
with bone-only metastases. Our second objective was to
compare progression-free survival (PFS) and overall
survival (OS) between patients with hormone receptor
(HR)
 tumors and bone-only metastases who received
combinatory therapy (chemotherapy followed by endo-
crine therapy, or endocrine therapy combined with mo-
lecular targeted therapy) and those treated with
endocrine or chemotherapy alone.
Patients and Methods. We retrospectively identified
351 breast cancer patients diagnosed with bone-only
metastasis in 1997–2008 at our institution.
Results. Patients with metastasis detected at the
time of their primary breast cancer diagnosis (rather
than at recurrence), a single metastasis, or asymp-
tomatic bone disease had a longer PFS interval, and
patients with a performance status of 0–1, a single
metastasis, or asymptomatic bone disease had a
longer OS time. Among patients with HR
 human
epidermal growth factor receptor (HER)-2
 disease,
combinatory therapy was associated with longer PFS
and OS times than with endocrine therapy. In multi-
variate analyses, combinatory therapy was not asso-
ciated with longer PFS or OS times than with
endocrinetherapy.AmongpatientswithHER-2
 dis-
ease, trastuzumab led to a longer PFS interval but no
difference in the OS time.
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INTRODUCTION
Bone metastases are common in patients with advanced
breast cancer. In a retrospective study of patients with met-
astatic breast cancer, bone was the most common site of
metastatic disease (70% of patients) [1]. Bone-only meta-
static breast cancer was first described in the 1970s and
1980s[2–8].Bone-onlymetastasishasbeenreportedtooc-
cur in 17%–37% of women with metastatic breast cancer
[4, 6, 9]. Its prognosis seems to be better than that of vis-
ceral metastasis. The median survival times from the diag-
nosisofmetastaticdiseasetodeathhavebeenreportedas22
monthsoverall,26monthsinpatientswithbonemetastases
only, 21 months in patients with bone and visceral metas-
tases, and 18 months in patients with visceral metastases
only[10].Additionalpreviousstudieshavealsoshownthat
patients with bone-only metastatic disease survive longer
thanpatientswithvisceralmetastases,withmediansurvival
times for patients with bone metastases in the range of
24–36 months [6, 9–12]. The more indolent disease course
may be the result of hormone-responsive disease—many
patients with bone-only metastases have hormone receptor
(HR)
 disease, which can be treated with endocrine (hor-
monal)therapy.Supportivecarewithbisphosphonatesmay
also contribute to the more indolent disease course [12].
Little information is available regarding the optimal
management and clinical outcome of bone-only metastases
in breast cancer patients. Current options for these patients
may include endocrine therapy, chemotherapy, a combina-
tion of the two, molecular targeted therapy, and i.v.
bisphosphonate therapy. External radiotherapy and ortho-
pedic interventions, when appropriate, to prevent or correct
pathological fractures are also an integral part of manage-
ment.Perezetal.[11]suggestedthat,forpatientswithbone
metastases, efforts should be made to select the least ag-
gressive therapy to avoid excessive toxicity; however, this
approach has not been evaluated for effectiveness in a clin-
icaltrialsetting.Forexample,manyinvestigatorshavesug-
gested using endocrine therapy, which is less toxic than
chemotherapy,totreatpatientswithHR
diseasethatisnot
life threatening [13]. It is unknown which treatment ap-
proach (endocrine therapy alone, chemotherapy alone,
combinatory therapy) prolongs survival in patients with
bone-only metastasis. Moreover, little is known about the
prognostic factors that may predict better or worse out-
comes among patients with bone-only metastases.
With these gaps in mind, the first objective of our study
was to define prognostic factors in breast cancer patients
with bone-only metastases. Our second objective was to
compare progression-free survival (PFS) and overall sur-
vival (OS) times among patients with bone-only metastatic
disease treated with combinatory therapy, endocrine ther-
apy alone, and chemotherapy alone.
PATIENTS AND METHODS
We retrospectively identified patients diagnosed with bone
metastasis at the time of initial staging or who developed
bone metastasis as the first recurrence site during follow-
up. Patients diagnosed from January 1, 1997 to December
31, 2008 at The University of Texas MD Anderson Cancer
Center were included in this analysis, and their records
were retrieved from the Department of Breast Medical On-
cologydatabase.Ofthe2,254patientsdiagnosedwithbone
metastases with or without nonskeletal metastases from
breast cancer, 756 were diagnosed with bone-only metasta-
ses. Of the 756 patients with bone-only metastases, 405
were excluded because the patients did not undergo fol-
low-up in our hospital (n  140), there was no medical
record in the Breast Medical Oncology files (n  42), the
patients had treatment at another hospital before coming to
our institution (n  208), or the patients had another malig-
nanttumoralongwithbreastcancer(n15).Thus,datafor
351 patients were evaluated. This study was approved by
MD Anderson Cancer Center’s institutional review board,
which waived the need for written informed consent be-
cause of the retrospective nature of the study.
Definition of Bone-Only Metastases
We defined patients with bone-only metastases as patients
with bone metastasis demonstrated by appropriate imaging
and/or biopsy and without nonskeletal distant metastases at
the time of their initial diagnosis of metastatic breast can-
cer.Wedefinedmetastasisatpresentationasbone-onlyme-
tastasis detected at the time of the patient’s initial diagnosis
of breast cancer, and we defined metastasis at recurrence as
bone-only metastasis detected after the completion of de-
finitive curative management of the primary breast tumor
and neoadjuvant and/or adjuvant systemic treatment. We
defined a single metastasis as one bone metastasis based on
imaging reports from a bone scan and/or positron emission
tomography/computed tomography imaging, and we de-
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We defined combinatory therapy as chemotherapy fol-
lowed by endocrine therapy before progression of disease
orasendocrinetherapycombinedconcurrentlywithmolec-
ular targeted therapy.
Staging and Pathology Review
Primarybreastcancerwasstagedaccordingtothesixthedi-
tion of the American Joint Committee on Cancer’s AJCC
Cancer Staging Manual [14]. Metastatic bone disease was
confirmed by histopathological analysis if specimens were
available. Primary tumors were graded using the modified
Black’s nuclear grading system [15] and histologically
classified using the World Health Organization criteria
[16]. A patient was considered to have human epidermal
growth factor receptor (HER)-2
 disease if the primary tu-
mor or a metastatic tumor had a score of 3 on HER-2 im-
munohistochemical analysis or if fluorescence in situ
hybridization revealed amplification of the HER2 gene. A
patientwasconsideredtohaveHR
diseaseif10%ofthe
tumor cells stained positive for estrogen receptor (ER) or
progesterone receptor on immunohistochemical analysis.
Statistical Methods
Meansandstandarddeviationswereusedtosummarizeage
at diagnosis. Frequencies and proportions were used to
presentthecategoricalclinicalcharacteristics.Pearson’s
2
testsandFisher’sexacttestswereusedtotestassociationof
treatmentsandcategoricalclinicalcharacteristics.Analysis
of variance was used to determine differences in the mean
age among patients in various treatment groups. PFS was
defined as the time interval from diagnosis of metastases to
progression, death, or the last follow-up date, whichever
occurred first. Patients who were alive without progression
at the last follow-up were censored in the PFS analyses. OS
was defined as the length of time from diagnosis of metas-
tases to death or to the last follow-up date if patients were
alive at the last follow-up. Patients who were alive at the
last follow-up were censored in the OS analyses. PFS and
OS were estimated by the Kaplan–Meier product-limit
method. Kaplan–Meier curves were used to present PFS
and OS durations over time for patients in each group. Uni-
variate and multivariate Cox proportional hazards regres-
sion models were used to assess the effect of treatment and
other predictive factors. The analyses were performed us-
ing SAS 9.1 for Windows (Copyright © 2002–2003 by the
SAS Institute Inc., Cary, NC) and the plots were generated
by S-PLUS 8.0 (Copyright © 1988, 2007 by Insightful
Corp., Seattle, WA).
RESULTS
Three hundred fifty-one patients whose clinical records
were available for review and who were diagnosed with
bone metastasis at initial staging or who later developed
bone metastasis as the first metastatic site were included in
this study (Table 1). Among them, 116 patients were diag-
nosed by biopsy. Of the 87 patients with a single bone me-
tastasis, 46 patients were confirmed to have metastasis by
biopsy.Atotalof182patientsexperienceddiseaseprogres-
sionanddied,111patientsexperienceddiseaseprogression
but were alive at last follow-up, four patients died without
diseaseprogression,and54patientswerealivewithoutpro-
gression at last follow-up. The median OS time was 51.9
months (95% confidence interval [CI], 46.8–57.5 months).
The median PFS interval was 16.3 months (95% CI, 13.6–
17.7 months). The median follow-up time was 33 months
(range, 4–143 months).
PatientcharacteristicsareshowninTable1.Onepatient
did not receive endocrine therapy or chemotherapy. We ex-
cluded this patient to analyze treatment effect. Comparing
the endocrine therapy, chemotherapy, and combinatory
therapy groups, there were significant differences in the
percentages of patients based on marker status, number of
bone metastases, Eastern Cooperative Oncology Group
(ECOG) performance status score, timing of metastasis di-
agnosis,andpresenceofbonepain(p.001,p.001,p
.030, p  .001, and p  .009, respectively). Patients who
receivedendocrinetherapywereolderthanpatientswhore-
ceived chemotherapy or combined treatment (p  .004).
Prognostic Factors
Table 2 shows the univariate analyses of PFS and OS by
clinical factors among all patients. Patients with metastasis
at presentation, a single bone metastasis, or asymptomatic
bone disease had a longer PFS interval than patients with
metastasis at recurrence, multiple metastases, or symptom-
atic bone disease. Patients with an ECOG performance sta-
tus score of 0 or 1, a single metastasis, or asymptomatic
bone disease had a longer OS time than patients with a per-
formance status score of 2 or 3, multiple sites of bone me-
tastasis, or symptomatic bone disease.
Combinatory Therapy
In our study, 60 patients received combinatory therapy. Of
thesepatients,51hadchemotherapyfollowedbyendocrine
therapy. The median duration of chemotherapy was 5.5
months (range, 1.0–24.0 months). Thirty-three patients re-
ceived an anthracycline regimen, 37 patients received tax-
anes, 13 patients received chemotherapy with trastuzumab,
and seven patients received high-dose chemotherapy. Of
the 18 patients with HER-2
 tumors, 12 received chemo-
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of the 60 patients received endocrine therapy combined with
molecular targeted therapy; two of those patients received en-
docrine therapy combined with trastuzumab, three received
endocrine therapy combined with imatinib, and four received
endocrine therapy combined with gefitinib.
Breast Cancer Subtypes and Treatment Outcome
Among patients with HR
HER-2
 tumors, combinatory
therapywasassociatedwithalongerPFSintervalthanwith
endocrine therapy (hazard ratio [HR], 0.68; p  .048) and
with chemotherapy (HR, 0.49; p  .011) (Fig. 1A). More-
over, combinatory therapy was associated with a longer OS
time than with endocrine therapy (HR, 0.48; p  .021) and
chemotherapy (HR, 0.32; p  .002) (Fig. 1B). In the mul-
tivariate Cox model of PFS and OS in patients with
HR
HER-2
tumors(Table3),patientswhoreceivedcom-
binatory therapy appeared to have a longer survival time,
but treatment was not significantly associated with PFS
(HR,1.24;p.287)orwithOS(HR,1.69;p.110)times
after adjustments were made for detection of metastasis at
presentation versus at recurrence, performance status (0 or
1 versus 2 or 3), number of bone metastases (single versus
multiple), and presence of bone pain.
Among patients with HR
HER-2
 tumors, combinatory
therapy was associated with a longer PFS interval than with
endocrine therapy (HR, 0.17; p  .001) and with chemother-
apy(HR,0.24;p.001)(Fig.1C).Combinatorytherapywas
alsostatisticallysignificantlyassociatedwithalongerOStime
thanwithchemotherapy(HR,0.28;p.037)butnotwithen-
docrine therapy (HR, 0.33; p  .052) (Fig. 1D).
In addition, among 63 patients with HER-2
HR
 or
HER-2
HR
tumors,36receivedtrastuzumabtherapy.Pa-
tientswhoreceivedtrastuzumabhadalongerPFStimethan
patients who did not receive trastuzumab (HR, 0.31; p 
.001) (Fig. 2A). Patients who received trastuzumab tended
to have a longer OS time, but treatment was not signifi-
cantlyassociatedwithOS(HR,0.58;p.120)(Fig.2B).In
the multivariate Cox model of PFS and OS in patients with
HER-2
 tumors, patients who received trastuzumab ther-
apy tended to have a long survival duration, and trastu-
zumab was significantly associated with a longer PFS time
(HR,0.32;p.001),buttrastuzumabwasnotsignificantly
associated with OS (HR, 0.59; p  .153) after adjustments
weremadefordetectionofmetastasisatpresentationversus
at recurrence, performance status (0 or 1 versus 2 or 3),
number of bone metastases (single versus multiple), and
presence or absence of bone pain (Table 4).
DISCUSSION
To our knowledge, this is the largest study documenting
treatment and patient outcomes in breast cancer patients
Table 1. Patient characteristics by treatment
Characteristic
Endocrine therapy,
n  212 (%)
Chemotherapy,
n  78 (%)
Combinatory therapy,
n  60 (%) p-value
Mean age at primary diagnosis (STD), yrs 53.1 (12.9) 48.1 (12.1) 49.5 (11.0) .004
Marker status
HR
HER-2
 193 (91%) 31 (40%) 39 (65%)
HER2
 19 (9%) 24 (31%) 20 (33%)
Triple negative 0 (0%) 21 (27%) 0 (0%) .001
n of bone metastases
Single 46 (22%) 13 (17%) 28 (47%) .001
Multiple 166 (78%) 65 (83%) 32 (53%)
ECOG performance status
0, 1 193 (91%) 67 (86%) 59 (98%) .030
2, 3 19 (9%) 11 (14%) 1 (2%)
Timing of metastasis diagnosis
At presentation with primary tumor 81 (38%) 36 (46%) 44 (73%) .001
At recurrence 131 (62%) 42 (54%) 16 (27%)
Bone pain
Asymptomatic 87 (41%) 34 (44%) 38 (63%) .009
Symptomatic 125 (59%) 44 (56%) 22 (37%)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; HER-2, human epidermal growth factor receptor 2; HR,
hormone receptor; STD, standard deviation.
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bone-onlymetastaseshadalongPFSinterval(median,16.3
months) and OS time (median, 51.9 months). Good prog-
nosticfactorsforsurvivalinpatientswithbone-onlymetas-
tases were a single metastasis, asymptomatic bone disease,
metastasis at presentation (rather than at recurrence), and a
good performance status.
Among the HR
HER-2
 group and the HR
HER-2

group, patients who received combinatory therapy had
longer survival than those who received chemotherapy or
Table 2. Univariate analyses of progression-free and overall survival by clinical factors for all patients
Progression-free survival Overall survival
Characteristic
Disease progression
or death, n (%) HR (95% CI) p-value Death, n (%) HR (95% CI) p-value
Age at primary diagnosis
50 yrs 140/161 (87%) Referent 88/161 (55%) Referent
50 yrs 157/190 (83%) 1.10 (0.88–1.38) .404 98/190 (52%) 0.85 (0.64–1.14) .279
Menopausal status
Premenopausal 124/143 (87%) Referent 77/143 (54%) Referent
Postmenopausal 168/203 (83%) 0.92 (0.73–1.17) .503 105/203 (52%) 1.03 (0.77–1.38) .846
Timing of metastasis
diagnosis
At presentation 132/161 (82%) Referent 73/161 (45%) Referent
At recurrence 165/190 (87%) 1.30 (1.03–1.64) .025 113/190 (59%) 1.29 (0.96–1.73) .088
Disease-free interval
1 yr 8/14 (57%) Referent 6/14 (43%) Referent
1 yr 156/176 (89%) 1.47 (0.72–2.99) .293 107/176 (61%) 1.28 (0.56–2.93) .553
3 yrs 45/54 (83%) Referent 35/54 (65%) Referent
3 yrs 119/136 (88%) 1.06 (0.94–1.18) .353 78/136 (57%) 0.96 (0.84–1.09) .520
5 yrs 119/138 (86%) Referent 86/138 (62%) Referent
5 yrs 45/52 (87%) 1.02 (0.96–1.10) .501 27/52 (52%) 0.84 (0.91–1.09) .837
ECOG performance status
score
0, 1 270/320 (84%) Referent 165/320 (52%) Referent
2, 3 27/31 (87%) 1.16 (0.78–1.73) .453 21/31 (68%) 2.13 (1.34–3.37) .001
ER status
Positive 262/304 (86%) Referent 158/304 (52%) Referent
Negative 35/46 (76%) 0.95 (0.67–1.36) .796 28/46 (61%) 1.36 (0.91–2.03) .138
HER-2 status
Positive 48/63 (76%) Referent 33/63 (52%) Referent
Negative 205/239 (86%) 1.35 (0.98–1.85) .063 116/239 (49%) 1.33 (0.90–1.96) .151
Nuclear grade
I or II 139/171 (81%) Referent 102/157 (65%) Referent
III 134/157 (85%) 0.79 (0.62–1.01) .057 71/157 (45%) 1.31 (0.96–1.78) .079
n of metastases
Single 70/87 (80%) Referent 36/87 (41%) Referent
Multiple 227/264 (86%) 1.61 (1.23–2.11) .001 150/264 (57%) 1.72 (1.20–2.48) .003
Bone pain
Asymptomatic 128/159 (81%) Referent 64/159 (40%) Referent
Symptomatic 169/192 (88%) 1.44 (0.14–1.81) .002 122/192 (64%) 1.48 (1.09–2.00) .011
Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; HER-2,
human epidermal growth factor receptor 2; HR, hazard ratio.
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tivariate analysis there was no statistically significant dif-
ference in terms of the PFS or OS time in patients treated
with combinatory therapy compared with those who re-
ceived endocrine therapy alone. However, this may be be-
cause of the limited number of patients in our study. In
addition, among those in the HER-2
 group, patients who
received trastuzumab tended to have a longer PFS interval
than those who did not receive trastuzumab.
To our knowledge, all studies reported to date have
shownarelativelylongsurvivaldurationinthesubgroupof
patients with bone-only metastases, with median survival
timesintherangeof24–36months[6,9–12].Cazzanigaet
al. [17] reported that patients with bone-only metastases
had a longer OS time than those with both bone and non-
skeletal metastases. In their study, the 2-year probabilities
forsurvivalaccordingtothepresenceofnonskeletalmetas-
tasesandtheirtimeofappearancewere0.74(95%CI,0.67–
0.79)forpatientswithbone-onlymetastases,0.38(95%CI,
0.25–0.51) for patients with nonskeletal metastases occur-
ringbeforebonemetastases,and0.56(95%CI,0.46–0.66)
for patients with concomitant nonskeletal and bone metas-
tases (p  .0001), after a median follow-up of 28 months
(range, 2–43 months). In our study, the median OS time of
4yearsforpatientswithbone-onlymetastaseswaslonger
than that observed in previously reported studies. Improve-
ments in the management of metastatic disease in the bone
canbeattributedtonewandmorespecificdiagnosticmeth-
odology, the use of orthopedic surgery, advances in radia-
tion therapy and chemotherapy, the use of radiolabeled
drugs, and new-generation bisphosphonates.
Previous studies have reported factors that affect prog-
nosisinbonemetastases.Cazzanigaetal.[17]reportedthat
the principal prognostic factors that correlated with OS af-
ter the appearance of bone metastases were tumor grade,
histological type, HR status, and occurrence of skeletal-
related events. Coleman et al. [12] reported that important
prognostic factors for survival after the development of
Figure 1. Kaplan–Meier curves. (A): Progression-free survival by treatment in patients with HR
HER-2
 tumors. (B): Overall
survival by treatment in patients with HR
HER-2
 tumors. (C): Progression-free survival by treatment in patients with
HR
HER-2
 tumors. (D): Overall survival by treatment in patients with HR
HER-2
 tumors.
Abbreviations:Chemo,chemotherapy;Com,combinatorytherapy;End,endocrinetherapy;HER-2,humanepidermalgrowth
factor receptor 2; HR, hormone receptor.
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icalgradeoftheprimarytumor,ERstatus,presenceofskel-
etal metastasis at initial breast cancer diagnosis, disease-
free interval, and age. Koizumi et al. [18] found that ER
status, progesterone receptor status, disease-free interval
(bone metastasis–free interval), the first site of nonskeletal
metastasis, and the number of bone lesions (solitary versus
multiple) were independent prognostic factors. Major et al.
[19]reportedthatthehydroxyproline–creatinineratioanda
positive progesterone receptor status were the only vari-
ables to significantly correlate with OS. Most of the previ-
ous studies included not only patients with bone-only
metastases but also patients with bone and nonskeletal me-
tastases. In our study, asymptomatic bone disease was
among the good prognostic factors for survival. Asymp-
tomatic patients may appear to have longer survival time
thansymptomaticpatientsbecauseoflead-timebias(theef-
fect of an early diagnosis).
Previous recommendations specified that endocrine
therapy was the preferred treatment to control symptoms,
Table 3. Multivariate Cox model of PFS and OS in patients with hormone receptor–positive, HER-2
 tumors
PFS OS
Variable HR (95% CI) p-value HR (95% CI) p-value
Treatment
Combinatory therapy Referent – Referent –
Endocrine therapy alone 1.24 (0.84–1.84) .287 1.69 (0.89–3.21) .110
Timing of metastasis diagnosis
At presentation Referent – Referent –
At recurrence 1.19 (0.89–1.59) .243 1.14 (0.76–1.69) .527
ECOG performance status score
0, 1 Referent – Referent –
2, 3 0.87 (0.51–1.50) .624 2.09 (1.15–3.82) .016
n of metastases
Single Referent – Referent –
Multiple 1.20 (0.86–1.68) .282 1.23 (0.75–1.95) .363
Bone pain
Asymptomatic Referent – Referent –
Symptomatic 1.38 (1.02–1.87) .037 1.57 (1.04–2.38) .031
Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HER-2, human epidermal growth
factor receptor 2; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.
Figure 2. Kaplan–Meier curves of progression-free survival (A) and overall survival (B) for patients with human epidermal
growth factor receptor 2–positive tumors by whether they received trastuzumab.
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preserving quality of life for patients with HR
HER-2

diseaseandbone-onlymetastases[8,13].However,ourret-
rospectivestudysuggeststhatcombinatorytherapyresulted
in longer survival than with endocrine therapy or with che-
motherapy alone. In multivariate analyses, the differences
in the PFS and OS times between patients who received
combinatory therapy and those who received endocrine
therapy alone did not reach statistical significance. This
loss of statistical significance is because the group treated
with combinatory therapy included more patients with per-
formance status scores of 0 or 1, a single metastasis, metas-
tasis at presentation, and no bone pain than the group that
received only endocrine therapy. In addition, among pa-
tients with HR
HER-2
 tumors, combinatory therapy that
included trastuzumab tended to be associated with longer
survival time than with endocrine therapy or with chemo-
therapy alone.
Treatment of bone-only metastases was reported in
1986 by Scheid et al. [6], who noted objective responses to
doxorubicin-containing combinatory chemotherapy (with
cyclophosphamide, 5-fluorouracil, ftorafur, or vincristine)
in 59% of patients: complete responses in 7% and partial
responsesin52%.ThemedianOSdurationwas28months,
and the median PFS interval was 14 months. Vredenburgh
et al. [20] reported a randomized trial of high-dose chemo-
therapy versus observation in women with bone-only me-
tastases; patients who received chemotherapy had a
significantlylongerevent-freesurvivalintervalwithnodif-
ference in OS. Our study included seven patients treated
with high-dose chemotherapy. Ueno et al. [21] reported
complete responses lasting nearly 9 years for two of six pa-
tientswithbone-onlymetastaticbreastcancerwhoreceived
bone-targeted radiation therapy using
166Ho-1,4,7,10-tet-
raazacyclododecane-1,4,7,10-tetramethylene-phospho-
nate.
Among patients with HER-2
 tumors in our study,
those who received trastuzumab tended to have longer sur-
vival than those who did not receive trastuzumab. Previous
studies have reported that trastuzumab prolongs survival in
patients with HER-2
 metastatic tumors, including bone
metastases [22–26]. However, no papers have reported that
trastuzumab is effective against bone-only metastases. In
our study, the number of patients with HER-2
 disease
treated with trastuzumab was too small to enable meaning-
ful conclusions. Our results indicate that trastuzumab may
be an effective treatment for bone-only metastases, al-
though further study is needed to establish which systemic
treatments are most effective.
Our study had some limitations. First, this was a retro-
spective evaluation of data collected from patients’ charts;
therefore, this study suffers from the bias associated with
anyretrospectivestudy,suchasinherentselectionbias.The
combinatory therapy received by patients included various
Table 4. Multivariate Cox model of PFS and OS in patients with HER-2
 tumors
PFS OS
Variable HR (95% CI) p-value HR (95% CI) p-value
Treatment
No trastuzumab Referent – Referent –
Trastuzumab 0.32 (0.17–0.61) .001 0.59 (0.28–1.22) .153
Timing of metastasis diagnosis
At presentation Referent – Referent –
At recurrence 1.76 (0.81–3.82) .154 1.87 (0.82–4.27) .137
ECOG performance status score
0, 1 Referent – Referent –
2, 3 1.41 (0.40–4.95) .589 4.70 (1.21–18.31) .026
Number of metastases
Single Referent – Referent –
Multiple 2.46 (1.23–4.92) .011 2.59 (1.04–6.47) .042
Bone pain
Asymptomatic Referent – Referent –
Symptomatic 0.57 (0.25–1.32) .192 0.41 (0.17–0.97) .043
Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HER-2, human epidermal growth
factor receptor 2; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.
162 Bone-Only Metastases of Breast Cancerdrugs, doses, and schedules. Patients were not randomized
to different treatments; there were significant differences
betweentreatmentgroupsinthenumberofbonemetastases
andECOGperformancestatusscores.Further,therewerea
substantial number of inevaluable patients resulting from
loss to follow-up and treatment at other hospitals. We con-
sidered disease HR
 if 10% of the tumor cells stained
positively for ER or progesterone receptor on immunohis-
tochemicalanalysis.ThecurrentAmericanSocietyofClin-
ical Oncology guideline recommends 1% tumor cell
staining for determination of ER positivity; however, our
data were collected prior to publication of the guideline in
2010. Finally we could not address whether metastatic new
sites of bone metastases or subsequent nonbone distant dis-
ease sites had an impact on outcome.
In summary, we identified good prognostic factors for
survival in patients with bone-only metastasis from breast
cancer. For patients with HR
 tumors and bone-only me-
tastases, we recommend that the standard therapy remain
endocrinetherapyalone.However,investigationofchemo-
therapy followed by endocrine therapy is needed to deter-
mine whether it prolongs survival over that seen with
endocrine therapy alone. Although our results can only be
considered hypothesis-generating, this hypothesis is worth
exploring. Which treatments most effectively prolong sur-
vival for patients with bone-only metastasis are still un-
known pending a prospective study to confirm our
observations.
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